3F81

Interaction of VHR with SA3

3F81 の概要

• エントリーDOI: 10.2210/pdb3f81/pdb
• 分子名称: Dual specificity protein phosphatase 3, 2-[(5~{E})-5-[[3-[4-(2-fluoranylphenoxy)phenyl]-1-phenyl-pyrazol-4-yl]methylidene]-4-oxidanylidene-2-sulfanylidene-1,3-thiazolidin-3-yl]ethanesulfonic acid (3 entities in total)
• 機能のキーワード: hydrolase, protein dual-specificity phosphatase, inhibitor, protein phosphatase
• 由来する生物種: Homo sapiens (human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 41729.32

構造登録者

Wu, S.,Mutelin, T.,Tautz, L. (登録日: 2008-11-11, 公開日: 2009-11-10, 最終更新日: 2023-09-06)

主引用文献

Wu, S.,Vossius, S.,Rahmouni, S.,Miletic, A.V.,Vang, T.,Vazquez-Rodriguez, J.,Cerignoli, F.,Arimura, Y.,Williams, S.,Hayes, T.,Moutschen, M.,Vasile, S.,Pellecchia, M.,Mustelin, T.,Tautz, L.
Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells.
J.Med.Chem., 52:6716-6723, 2009

PubMed Abstract: Loss of VHR phosphatase causes cell cycle arrest in HeLa carcinoma cells, suggesting that VHR inhibition may be a useful approach to halt the growth of cancer cells. We recently reported that VHR is upregulated in several cervix cancer cell lines as well as in carcinomas of the uterine cervix. Here we report the development of multidentate small-molecule inhibitors of VHR that inhibit its enzymatic activity at nanomolar concentrations and exhibit antiproliferative effects on cervix cancer cells. Chemical library screening was used to identify hit compounds, which were further prioritized in profiling and kinetic experiments. SAR analysis was applied in the search for analogs with improved potency and selectivity, resulting in the discovery of novel inhibitors that are able to interact with both the phosphate-binding pocket and several distinct hydrophobic regions within VHR's active site. This multidentate binding mode was confirmed by X-ray crystallography. The inhibitors decreased the proliferation of cervix cancer cells, while growth of primary normal keratinocytes was not affected. These compounds may be a starting point to develop drugs for the treatment of cervical cancer.

PubMed: 19888758
DOI: 10.1021/jm901016k

実験手法

X-RAY DIFFRACTION (1.9 Å)